Selected article for: "major histocompatibility and MHC class"
Author: Kwon, Young Jik; Standley, Stephany M.; Goh, Sarah L.; Fréchet, Jean M.J.
Title: Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles
  • Cord-id: cz2h0hml
  • Document date: 2005_7_20
    • ID: cz2h0hml
    Snippet: Acid-degradable cationic nanoparticles encapsulating a model antigen (i.e., ovalbumin) were prepared by inverse microemulsion polymerization with acid-cleavable acetal cross-linkers. Incubation of these degradable nanoparticles with dendritic cells derived from bone marrow (BMDCs) resulted in the enhanced presentation of ovalbumin-derived peptides, as quantified by B3Z cells, a CD8(+) T cell hybridoma. The cationic nature of the particles contributed to the increased surface endocytosis (or phag
    Document: Acid-degradable cationic nanoparticles encapsulating a model antigen (i.e., ovalbumin) were prepared by inverse microemulsion polymerization with acid-cleavable acetal cross-linkers. Incubation of these degradable nanoparticles with dendritic cells derived from bone marrow (BMDCs) resulted in the enhanced presentation of ovalbumin-derived peptides, as quantified by B3Z cells, a CD8(+) T cell hybridoma. The cationic nature of the particles contributed to the increased surface endocytosis (or phagocytosis) observed with BMDCs, which is the first barrier to overcome for successful antigen delivery. The acid sensitivity of the particles served to direct more ovalbumin antigens to be processed into the appropriately trimmed peptide fragments and presented via the major histocompatibility complex (MHC) class I pathway following hydrolysis within the acidic lysosomes. It was also shown that adjuvant molecules such as unmethylated CpG oligonucleotides (CpG ODN) and anti-interleukin-10 oligonucleotides (AS10 ODN) could be co-delivered with the protein antigen for maximized cellular immune response.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and adaptive immunity immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and adaptive immunity immunity innate: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and additional hour: 1, 2
    • acute respiratory syndrome and additional knowledge: 1, 2
    • acute respiratory syndrome and adjuvant nucleotide: 1
    • acute respiratory syndrome and local inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
    • acute respiratory syndrome and low antigen presentation: 1
    • acute respiratory syndrome and low concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52
    • acute respiratory syndrome and low efficiency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome and lymph spleen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
    • acute respiratory syndrome and lymph spleen node: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and lysis buffer: 1, 2, 3
    • acute respiratory syndrome and lysosomal compartment: 1, 2
    • adaptive immunity and local inflammation: 1, 2, 3, 4, 5
    • adaptive immunity and low concentration: 1
    • adaptive immunity and lysosomal degradation: 1, 2, 3
    • adaptive immunity and lysosomal endosomal: 1
    • low concentration and lymph spleen: 1
    • low concentration and lysis buffer: 1, 2